UCB and Biogen say their first phase 3 trial of their systemic lupus erythematosus ... GSK's Benlysta (belimumab), AstraZeneca's Saphnelo (anifrolumab), and Otsuka's Lupkynis (voclosporin).

Adding anifrolumab to standard treatment for systemic lupus erythematosus led to faster achievement of low disease activity ...

For patients with moderately to severely active systemic lupus erythematosus (SLE), anifrolumab is associated with less organ damage after 208 weeks compared with patients receiving standard of ...

Recent findings from the RESOLVE-1 trial highlight mycophenolate mofetil's efficacy in treating diffuse cutaneous systemic ...

Two new studies led by researchers at the Hospital for Special Surgery (HSS) have uncovered key biological mechanisms driving systemic sclerosis (SSc), or scleroderma – a rare and often devastating ...

Adds to Extensive Preclinical and Early Clinical Evidence that Nebokitug Interferes with Key Features of Systemic Sclerosis TEL AVIV, Israel, March 06, 2025 (GLOBE NEWSWIRE) -- Chemomab ...

Systemic sclerosis (SSc) is a complex autoimmune disease characterized by widespread vascular abnormalities, immune system activation, and skin and internal ...

Scleroderma affects approximately 300,000 people in the U.S., with about one-third developing systemic disease, which can affect major organs such as the lungs, kidneys or heart.